18F-FDG PET早期评估疗效影响接受新辅助伊马替尼治疗的胃肠道间质瘤患者的管理
该回顾性研究基于荷兰GIST登记数据库,评估63例接受新辅助伊马替尼治疗的GIST患者中70次18F-FDG PET早期疗效评估对管理决策的影响。PET使27.1%的患者管理发生改变,管理改变与缺乏代谢反应(P < 0.001)及非KIT外显子11突变型GIST(P < 0.001)强相关。作者认为对非KIT外显子11突变患者行早期18F-FDG PET评估常导致管理改变,应视为新辅助治疗GIST患者的标准诊疗。
要点
- 63例GIST患者共行70次18F-FDG PET早期评估新辅助伊马替尼疗效。
- PET使27.1%的患者管理发生改变。
- 管理改变与缺乏代谢反应及非KIT外显子11突变强相关(均P < 0.001)。
核心结论
- 对新辅助伊马替尼治疗的GIST患者行18F-FDG PET早期疗效评估常导致管理改变,尤其在非KIT外显子11突变患者中。
- 作者认为18F-FDG PET早期疗效评估应视为接受新辅助治疗GIST患者的标准诊疗。
研究设计与样本
- 回顾性研究,基于荷兰GIST登记数据库,纳入接受新辅助伊马替尼治疗的63例GIST患者,共获取70次18F-FDG PET扫描用于早期疗效评估。
主要发现
- 18F-FDG PET早期疗效评估使27.1%的患者管理发生改变。
- 管理改变与缺乏代谢反应强相关(P < 0.001)。
- 管理改变与非KIT外显子11突变型GIST强相关(P < 0.001)。
临床怎么用
- 作者认为,对非KIT外显子11突变的GIST患者行18F-FDG PET早期疗效评估常导致管理改变,应视为新辅助治疗GIST患者的标准诊疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-FDG PET has previously been proven effective as an early way to evaluate the response of gastrointestinal stromal tumors (GISTs) to imatinib treatment. However, it is unclear whether early evaluation of response affects treatment decisions in GIST patients treated with neoadjuvant intent. Methods: We retrospectively scored changes in management based on early evaluation of response by 18F-FDG PET in patients in the Dutch GIST registry treated with neoadjuvant imatinib. Results: Seventy 18F-FDG PET scans were obtained for 63 GIST patients to evaluate for an early response to neoadjuvant imatinib. The scans led to a change in management in 27.1% of the patients. Change in management correlated strongly with lack of metabolic response (P < 0.001) and non-KIT exon 11-mutated GISTs (P < 0.001). Conclusion: Performing 18F-FDG PET for early evaluation of response often results in a change of management in GIST patients harboring the non-KIT exon 11 mutation and should be considered the standard of care in GIST patients treated with neoadjuvant intent.
引用
- Farag S, Geus-Oei LF, van der Graaf WT, et al. Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. J Nucl Med. 2017. PMID: 28970330. doi:10.2967/jnumed.117.196642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。